Home > Back to Publisher > Report Information
Alzheimer's and Parkinson's DiseaseGlobal Industry AnalystsMay 1, 2008 530 Pages - SKU: GJOB1874973 |
| Countries covered: Global This report analyzes the worldwide markets for Alzheimer’s and Parkinson’s Disease in Millions of US$. The Major product segments Analyzed are Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors, & NMDARA), and Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, & Other PD Drugs (Include COMT Inhibitors, MOA-B Inhibitors, and Dopamine Amplifiers). The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, and Rest of World. Annual forecasts are provided for each region for the period of 2000 through 2015. The report profiles 87 companies including many key and niche players worldwide such as Boehringer Ingelheim, Bristol-Myers Squibb Co., Eisai Inc., Eli Lilly and Company, Forest Pharmaceuticals, GlaxoSmithKline PLC, H. Lundbeck A/S, Merz Pharmaceuticals GMBH, Novartis AG, Ortho-McNeil Neurologics, Inc., Pfizer Inc., Roche, Shire Pharmaceuticals Group PLC, and Valeant Pharmaceuticals International. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources. Please note: Reports are sold as single-site single-user licenses. The delivery time for hard copies is between 3-5 business days, as each hard copy is custom printed for the organization ordering it. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location. Adobe Acrobat Reader 7.0 is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report. Titles available via "online download" are not affected by this and are still delivered to your reading room immediately. Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher. |
- I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
- Study Reliability and Reporting Limitations
- Disclaimers
- Data Interpretation & Reporting Level
- Quantitative Techniques & Analytics
- Product Definitions and Scope of Study
- Product Segments
- Anti-Alzheimer’s Disease Drugs
- Cholinesterase Inhibitors
- NMDARA
- Anti-Parkinson’s Disease Drugs
- Dopaminergic Agents (Levodopa/Carbidopa)
- Dopamine Agonists
- Other PD Drugs (Include COMT Inhibitors, MOA-B Inhibitors, and Dopamine
- Amplifiers)
- COMT Inhibitors
- MAO-B Inhibitors
- Dopamine Amplifiers
- II. EXECUTIVE SUMMARY
- 1. Outlook
- Current and Future Analysis
- 2. Neurodegenerative Diseases Market - A Brief Overview
- Key Brands in NDD Market
- Table 1: Leading Drugs in the Global Neurodegenerative Disease Market (2004): Percentage Breakdown by Sales Revenues for Razadyne, Aricept, Exelon, Namenda, Sifrol / Mirapex, Requip, Cabaser, Madopar, Siemet, Permax, and Others (includes corresponding Graph/Chart)
- Factors Affecting Market
- Major Growth Drivers
- Major Growth Inhibitors
- Market Trends
- High Prevalence Rates Drive Market Growth
- Rapid Growth of Ageing Population
- Price Hikes and Government Caps
- Combination Therapy Gaining Ground
- Research & Development
- Future Holds Promise
- 3. Alzheimer’s Market Overview
- A Peek at Anti-AD Drug Market
- Impact of Dementia
- Epidemiology
- Table 2: World Alzheimer’s Disease Prevalence for Years 2000 through 2010: Number of Patients in Thousands by Country/Region for US, Canada, Japan, Europe (Germany, France, UK, Italy, Spain, and Rest of Europe), and Rest of World (includes corresponding Graph/Chart)
- Table 4: Alzheimer’s Disease Diagnosis in Top Seven Countries (2005): Percentage of Diagnosed Patients in the US, Japan, Germany, France, Italy, Spain, and the UK (includes corresponding Graph/Chart)
- Patient Growth Drivers
- Demographics Spell Opportunities
- High Growth Rates for AD Drugs
- The Impact of Aricept
- Epic of NMDARA
- Strengths
- Weaknesses
- Future Therapies
- How Successful will the Late Stage Therapies be?
- A Geographic Milieu
- US
- Europe
- Japan
- Alternative Drug Delivery Technologies Gaining Ground
- Transdermal Patch
- Domination of Acetyl Cholinesterase Inhibitors
- Dramatic Changes in Market Lie Ahead
- Advances in Next-Generation Treatments
- Beta Amyloid Hypothesis
- Growth Drivers
- Ageing Baby Boomers Drive AD Market
- Table 5: AD Frequency Rate (%) (includes corresponding Graph/Chart)
- New Hypothesis Enables Effective Treatment
- Unmet Medical Needs Drive Market Growth
- Growth Inhibitors
- Link with Other Aliments
- Misdiagnosis
- Patient Awareness
- Medical Refunds
- Competitive Landscape
- Pharmaceutical Majors Rule the Market
- Eisai/Pfizer
- Novartis
- Shire/Johnson & Johnson
- Lundbeck/Forest
- Ipsen and UCB
- Table 6: Leading Brands in the Global Anti- Alzheimer’s Drug Market (2005): Percentage Breakdown by Sales Revenues for Aricept, Exelon, Razadyne, Axura, Ebixa, Namenda, and Others (includes corresponding Graph/Chart)
- Year of Approval of AD Drugs in Leading Countries
- Compounds in Pipeline
- Outlook for AD Drugs Market
- 4. Parkinson’s Disease Market Overview
- An Alluring Market
- Prevalence
- Table 7: World Parkinson’s Disease Prevalence for Years 2000 through 2010: Number of Patients in Thousands by Country/Region for US, Canada, Japan, Europe (Germany, France, UK, Italy, Spain, Rest of Europe), and Rest of World (includes corresponding Graph/Chart)
- Current Treatments
- New Medicines on the Horizon
- New Findings
- Product Launches Through 2009
- Dominance of Dopamine Agonists
- Revival Revels in Other Anti-PD Drugs Segment
- COMT Inhibitors Growing Fastest
- Key Market Drivers
- Rising Awareness Magnifies Patient Base
- Emergence of Dopamine Agonists as First Line Treatment Drives Market Growth
- The Debut of Stalevo
- Unmet Clinical Needs Show Mammoth Prospects
- Key Market Inhibitors
- Limitations of Existing Medicines Inhibit Market Growth
- Under-Diagnosis Restrains Market Potential
- Generic Competition from L-Dopa and Carbidopa Curbs Market Growth
- Restricted Term of Dopamine Agonists Usage Delays Market Growth
- 5. Disease Overview
- Alzheimer's Disease
- Definition
- The Cause
- Finding AD
- Prevention
- Treatment
- Parkinson’s Disease
- Definition
- Pathophysiology
- Diagnosis
- Prevalence
- Treatment
- Surgical Intervention
- 6. Drug Classification
- Anti-Alzheimer’s’ Disease Drugs
- NMDARA
- Memantine
- Cholinesterase Inhibitors (ChEIs)
- Donepezil (Aricept)
- Rivastigmine (Exelon)
- Galantamine Hydrobromide (Razadyne)
- Tacrine (Cognex)
- Other Alternatives
- Vitamin E
- Estrogen Therapy
- Anti-Inflammatory Drugs
- NSAIDs (Non-Steroidal Anti-Inflammatory Drugs)
- Antioxidants
- Vaccine
- Gingko Biloba
- Pure Medical Nicotine
- Anti-Parkinson’s Disease Drugs
- Dopaminergic agents
- Levodopa/Carbidopa
- Dopamine Agonists
- Pergolide/Permax
- Bromocriptine/Parlodel
- Ropinirole/Requip
- Pramipexole/Mirapex
- Cabergoline/Dostinex
- Apomorphine/Apokyn
- Other Dopamine Agonists
- Other PD Drugs
- COMT Inhibitors
- Tolcapone (Tasmar)
- Entacapone (Comtan)
- MAO-B Inhibitors
- Dopamine Amplifiers
- Anticholinergics
- 7. Future Therapies
- Alzheimer’s Disease
- Key Pipeline Products
- Phenserine
- Ropern
- Alzhemed
- MEM 1003
- Ampakine Compounds
- Parkinson’s Disease
- Key Pipeline Products
- Adenosine A2a Antagonist
- Spheramine®
- Safinamide
- O-1369
- 8. New Findings
- Risedronate Minimizes Risk of Hip Fractures in PD Patients
- Researchers Identify New Genes Responsible for AD
- Researchers Establish a New Link Between Loneliness and AD
- Researchers Try to Identify Early Stages of AD
- SORL1 - The New Gene Found to be Responsible for AD
- Scientists Conduct Research Work on CERE-120 Gene Therapy
- Researchers Find New Snail Toxin for Nervous System Disorders
- Researchers Study Anti-PD Properties of Nicotine
- Researchers Establish New Link Between Pesticides and PD
- Study Relates AD to the Quantity of Amyloid Protein
- Researchers Establish Effectiveness of Gene Therapy on AD Patients
- Scientists Use Electric Current to Treat PD Patients
- Scientists Prove Earlier Assumptions Wrong
- Scientists Discover 2 Distinct Types of MCIs
- 9. Recent Industry Activity
- Eisai Acquires MGI Pharma
- Eli Lilly Begins Phase III Clinical Trial of Alzheimer's Disease Treatment
- Merz Licenses Anti-Alzheimer’s Drug Technology from TAU
- Eisai Acquires Morphotek
- Transition Therapeutics Acquires NeuroMedix
- Evotec Teams Up with Boehringer Ingelheim
- Siemens Signs Partnership Agreement with Wyeth
- Digilab Receives Notice of Allowance for New Alzheimer's Biomarker
- Pfizer Joins Forces with Genizon
- Intellect Signs Licensing Agreement with IBL
- Boehringer Ingelheim signs R&D agreement with Ablynx
- Avicena Teams Up with NINDS for Phase III Trial of PD-02
- Prana Begins Phase II clinical trial for PBT2
- Idera Teams Up with Merck
- Merck Signs R&D Agreement with Neuroptix
- Neuro-Hitech Takes Over Q-RNA
- Neurogen Inks Licensing Agreement with Wyeth
- Acumen Revises License Agreement with Merck
- Newron Begins 2nd Phase III clinical trial for Safinamide
- Newron Inks Global Licensing Agreement with Serono
- Pfizer Inks License Agreement with TransTech
- CeNeS Renews R&D Agreement with Tripos
- Athenagen Acquires Zapaq
- Neuren Starts Pre-clinical Studies of Anti-PD Drug - NNZ-2591
- Teva Receives Health Canada Clearance for Azilect
- Valeant Introduces Zelapar Anti-PD Tablets in the US
- Merck to Halt Further Development of Anti-PD Drug Called Sarizotan
- Amarin Obtains Global Rights for New Apomorphine Formulation
- FDA Clears Exelon for Parkinson's Disease
- Neuropharma Receives German Clearance for Phase 1 Clinical Trials of NP031112
- Pfizer Takes Over Rinat
- TorreyPines Begins 2nd Phase-I clinical trial for NGX267
- Kyowa Hakko Inks Licensing Agreement with Britannia
- Schwarz Pharma Receives EMEA Clearance for Neupro
- Evotec Inks Licensing Agreement with Roche
- RheoGene Receives Funds from MJFF
- Eisai Initiates Phase I clinical trial for E2012
- Apokyn(R) Receives Approval in North America
- FDA Approves Azilect
- Voyager Completes Phase II Study for of Leuprolide Acetate
- New Discovery for the Treatment of Alzheimer's Disease in Canada
- Ortho-McNeil Launches Razadyne™ ER
- Flurizan Enters Phase II Clinical Trials
- Axonyx Releases Supplementary Results of Phase III Trial for Phenserine
- Predix Pharmaceuticals Starts Phase Ib Trials of 5-HT4 Agonist
- BrainStorm Pronounces Advantages of GDNF Producing Stem Cells in Parkinson's Animal
- Models
- Predix’s PRX-03140 Completes First Clinical Trial in Alzheimer's Disease
- Galapagos and Senexis Expand Collaboration
- Novartis Joins Forces with Ono to Develop and Market AD Transdermal Patch
- Neurologix Posts Interim Results of Phase I Gene Therapy
- GB Therapeutics Receives License for CHF1512
- Alzhemed™ Begins Phase III Trials
- Newron Commences Phase III Trial With Safinamide
- Ceregene Bags FDA Approval for Gene Therapy Alzheimer's Study
- Memantine Drug Receives Approval from FDA for Treatment of Alzheimer’s
- FDA Grants Fast Track Designation
- Ester Neurosciences Joins Forces with Pharmacopeia
- 10. Focus on Select Players
- Boehringer Ingelheim (Germany)
- Bristol-Myers Squibb Co. (USA)
- Eisai Inc. (USA)
- Eli Lilly and Company (USA)
- Forest Pharmaceuticals (USA)
- GlaxoSmithKline PLC (UK)
- H. Lundbeck A/S (Denmark)
- Merz Pharmaceuticals GMBH (Germany)
- Novartis AG (Switzerland)
- Ortho-McNeil Neurologics, Inc. (USA)
- Pfizer Inc (US)
- Roche (Switzerland)
- Shire Pharmaceuticals Group PLC (UK)
- Valeant Pharmaceuticals International (USA)
- 11. Global Market Perspective
- Table 8: World Recent Past, Current & Future Market Analysis for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Geographic Region - US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
- Table 9: World Long-term Projections for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Geographic Region - US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
- Table 10: World 10-Year Perspective for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart)
- Table 11: World Recent Past, Current & Future Market Analysis for Anti-Alzheimer’s Disease Drugs by Geographic Region - US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
- Table 12: World Long-term Projections for Anti-Alzheimer’s Disease Drugs by Geographic Region - US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
- Table 13: World Recent Past, Current & Future Market Analysis for Anti-Alzheimer’s Disease Drugs by Product Segment -Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
- Table 14: World Long-term Projections for Anti-Alzheimer’s Disease Drugs by Product Segment -Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
- Table 15: World 10-Year Perspective for Anti-Alzheimer’s Disease Drugs by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart)
- Table 16: World 10-Year Perspective for Anti-Alzheimer’s Disease Drugs by Product Segment - Percentage Breakdown of Dollar Sales for Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)) Markets for 2003, 2008 & 2012
- Table 17: World Recent Past, Current & Future Market Analysis for Cholinesterase Inhibitors by Geographic Region - US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
- Table 18: World Long-term Projections for Cholinesterase Inhibitors by Geographic Region - US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
- Table 19: World 10-Year Perspective for Cholinesterase Inhibitors by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart)
- Table 20: World Recent Past, Current & Future Market Analysis for NMDARA (N-methyl, D-Aspartate Receptor Antagonists)) by Geographic Region - US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2002 through 2010 (includes corresponding Graph/Chart)
- Table 21: World Long-term Projections for NMDARA (N-methyl, D-Aspartate Receptor Antagonists)) by Geographic Region - US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
- Table 22: World 9-Year Perspective for NMDARA (N-methyl, D-Aspartate Receptor Antagonists)) by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, and Rest of World Markets for Years 2004, 2008 & 2012 (includes corresponding Graph/Chart)
- Table 23: World Recent Past, Current & Future Market Analysis for Anti-Parkinson’s Disease Drugs by Geographic Region - US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
- Table 24: World Long-term Projections for Anti-Parkinson’s Disease Drugs by Geographic Region - US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
-
- Table 25: World Recent Past, Current & Future Market Analysis for Anti-Parkinson’s Disease Drugs by Product Segment - Dopaminergic agents, Dopamine Agonists, and Other PD Drugs Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
- Table 26: World Long-term Projections for Anti-Parkinson’s Disease Drugs by Product Segment - Dopaminergic agents, Dopamine Agonists, and Other PD Drugs Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
- Table 27: World 10-Year Perspective for Anti-Parkinson’s Disease Drugs by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart)
- Table 28: World 10-Year Perspective for Anti-Parkinson’s Disease Drugs by Product Segment - Percentage Breakdown of Dollar Sales for Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)
- Table 29: World Recent Past, Current & Future Market Analysis for Dopaminergic Agents by Geographic Region - US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
- Table 30: World Long-term Projections for Dopaminergic Agents by Geographic Region - US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
- Table 31: World 10-Year Perspective for Dopaminergic Agents by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart)
- Table 32: World Recent Past, Current & Future Market Analysis for Dopamine Agonists by Geographic Region - US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
- Table 33: World Long-term Projections for Dopamine Agonists by Geographic Region - US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
- Table 34: World 10-Year Perspective for Dopamine Agonists by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart)
- Table 35: World Recent Past, Current & Future Market Analysis for Other PD Drugs by Geographic Region - US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
-
- Table 36: World Long-term Projections for Other PD Drugs by Geographic Region - US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
-
- Table 37: World 10-Year Perspective for Other PD Drugs by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart)
- III. MARKET
- 1. The United States
- A. Market Analysis
- Current & Future Analysis
- AD Market Overview
- Approval of Cholinesterase Inhibitors for MCI to Drive Market
- Competitive Landscape
- Table 38: Leading Therapeutics in the North American Alzheimer’s Disease Market (2005 & 2004): Percentage Breakdown by New Prescription for Aricept, Exelon, Namenda, and Razadyne (includes corresponding Graph/Chart)
- Status of AD Drugs
- New Products in Clinical Trails
- Prevalence
- Table 39: Alzheimer’s Disease Prevalence in the US for Years 2005 through 2010 (includes corresponding Graph/Chart)
- PD Therapies Market
- Levodopa/Carbidopa on Declining Spree
- Competition
- Table 40: Leading Brands in the US PD Therapeutics Market (2004-2006E): Percentage Breakdown by Prescription for Generic Amantadine, Generic Benzitropine, Generic Levodopa/Carbidopa, Comtan, Mirapex, Requip, Generic Selegiline, Sinemet/Sinemet CR, Rasagiline, and Others (includes corresponding Graph/Chart)
- Patent Expiry Status
- Patent Expiry Status of Parkinson’s Disease Drugs in the US
- New Brands and Pipeline Analysis
- PD Prevalence
- New Findings
- Strategic Corporate Developments
- Key Players
- B. Market Analytics
- Table 41: US Recent Past, Current & Future Analysis for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment - Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
- Table 42: US Long-term Projections for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment - Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
- Table 43: US 10-Year Perspective for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment - Percentage Breakdown of Dollar Sales for Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)
- 2. Canada
- A. Market Analysis
- Current & Future Analysis
- Prevalence
- Strategic Corporate Developments
- B. Market Analytics
- Table 44: Canadian Recent Past, Current & Future Analysis for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment - Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
- Table 45: Canadian Long-term Projections for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment - Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
- Table 46: Canadian 10-Year Perspective for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment - Percentage Breakdown of Dollar Sales for Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)
- 3. Japan
- A. Market Analysis
- Current & Future Analysis
- Prevalence
- Strategic Corporate Developments
- B. Market Analytics
- Table 47: Japanese Recent Past, Current & Future Analysis for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment - Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
- Table 48: Japanese Long-term Projections for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment - Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
- Table 49: Japanese 10-Year Perspective for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment - Percentage Breakdown of Dollar Sales for Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)
- 4. Europe
- A. Market Analysis
- Current & Future Analysis
- Prevalence
- Alzheimer’s Disease
- Table 50: European Alzheimer’s Disease Prevalence For Years 2000 through 2010: Number of Patients (in ‘000) by Country/Region for Germany, France, UK, Italy, Spain, and Rest of Europe (includes corresponding Graph/Chart)
- Parkinson’s Disease
- Table 51: European Parkinson’s Disease Prevalence For Years 2000 through 2010: Number of Patients (in ‘000) by Country/Region for Germany, France, UK, Italy, Spain, and Rest of Europe (includes corresponding Graph/Chart)
- Competitive Scenario
- Table 52: Leading Brands in the European Alzheimer’s Disease Market (2005): Percentage Breakdown by New Prescription for Aricept, Ebixa/Auxura, Exelon, and Razadyne (includes corresponding Graph/Chart)
- Strategic Corporate Developments
- B. Market Analytics
- Table 53: European Recent Past, Current & Future Analysis for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Geographic Region - Germany, France, UK, Italy, Spain, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
- Table 54: European Long-term Projections for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Geographic Region - Germany, France, UK, Italy, Spain, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
- Table 55: European Recent Past, Current & Future Analysis for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment - Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
- Table 56: European Long-term Projections for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment - Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
- Table 57: Rest of Europe 10-Year Perspective for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Geographic Region - Percentage Breakdown of Dollar Sales for Germany, France, UK, Italy, Spain, and Rest of Europe Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)
- Table 58: Rest of Europe 10-Year Perspective for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment - Percentage Breakdown of Dollar Sales for Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)
- 4a. Germany
- A. Market Analysis
- Current & Future Analysis
- Prevalence
- Strategic Corporate Developments
- Key Players
- B. Market Analytics
- Table 59: German Recent Past, Current & Future Analysis for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment - Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
- Table 60: German Long-term Projections for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment - Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
- 4b. France
- A. Market Analysis
- Current & Future Analysis
- Prevalence
- B. Market Analytics
- Table 62: French Recent Past, Current & Future Analysis for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment - Anti- Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
- Table 63: French Long-term Projections for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment - Anti- Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
- Table 64: French 10-Year Perspective for Anti- Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment - Percentage Breakdown of Dollar Sales for Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)
- 4c. United Kingdom
- A. Market Analysis
- Current & Future Analysis
- Prevalence
- New Findings
- Strategic Corporate Developments
- Key Players
- B. Market Analytics
- Table 65: UK Recent Past, Current & Future Analysis for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment - Anti- Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
- Table 66: UK Long-term Projections for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment - Anti- Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
- Table 67: UK 10-Year Perspective for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment - Percentage Breakdown of Dollar Sales for Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)
- 4d. Italy
- A. Market Analysis
- Current & Future Analysis
- Prevalence
- Strategic Corporate Developments
- B. Market Analytics
- Table 68: Italian Recent Past, Current & Future Analysis for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment - Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
- Table 69: Italian Long-term Projections for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugsby Product Segment - Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
- 4e. Spain
- A. Market Analysis
- Current & Future Analysis
- Prevalence
- B. Market Analytics
- Table 71: Spanish Recent Past, Current & Future Analysis for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment - Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
- Table 72: Spanish Long-term Projections for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment - Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
- Table 73: Spanish 10-Year Perspective for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment - Percentage Breakdown of Dollar Sales for Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)
- 4f. Rest of Europe
- A. Market Analysis
- Current & Future Analysis
- Prevalence
- New Findings
- Strategic Corporate Developments
- Key Players
- B. Market Analytics
- Table 74: Rest of Europe Recent Past, Current & Future Analysis for Anti-Alzheimer’s and Anti- Parkinson’s Disease Drugs by Product Segment - Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
- Table 75: Rest of Europe Long-term Projections for Anti-Alzheimer’s and Anti- Parkinson’s Disease Drugs by Product Segment - Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
- Table 76: Rest of Europe 10-Year Perspective for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment - Percentage Breakdown of Dollar Sales for Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)
- 5. Rest of World
- A. Market Analysis
- Current & Future Analysis
- Prevalence
- Strategic Corporate Developments
- B. Market Analytics
- Table 77: Rest of World Recent Past, Current & Future Analysis for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment - Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
- Table 78: Rest of World Long-term Projections for Anti-Alzheimer’s & Anti-Parkinson’s Disease Drugs by Product Segment - Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
- Table 79: Rest of World 10-Year Perspective for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment - Percentage Breakdown of Dollar Sales for Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)
- IV. COMPETITIVE LANDSCAPE
- Total Companies Profiled: 87 (including Divisions/Subsidiaries - 105)
- Region/Country Players
- The United States 51
- Canada 5
- Japan 3
- Europe 36
- France 1
- Germany 9
- The United Kingdom 11
- Italy 2
- Spain 3
- Rest of Europe 10
- Asia-Pacific (Excluding Japan) 5
- Middle East 5
Table 3: Alzheimer’s Disease Prevalence in Top Seven Countries (US, Japan, Germany, France, UK, Italy, and Spain) for Years 2001 through 2010: Number of Patients (in ‘000) Diagnosed and Treated by Disease Severity (Mild Stage, Moderate Stage, and Late Stage) (includes corresponding Graph/Chart)
Table 61: German 10-Year Perspective for Anti- Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment - Percentage Breakdown of Dollar Sales for Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)
Table 70: Italian 10-Year Perspective for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment - Percentage Breakdown of Dollar Sales for Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)
More Global Parkinson's Disease Reports
Parkinson's Disease Therapeutics - Global Drug Forecasts and Treatment Analysis to 2020 by
GlobalData
Parkinson's Disease Therapeutics - Global Drug Forecasts and Treatment Analysis to 2020 Summary GlobalData, the industry analysis specialist, has released its new report, “Parkinson's Disease Therapeutics - ...
Parkinson's Disease: World Drug Market 2011-2021 by
Visiongain
What are the commercial prospects for the treatment of Parkinson's disease? Visiongain's report shows you potential drug revenues to 2021. Find opportunities and forecasts.
...
Neurodegenerative Drugs by
Global Industry Analysts
This report analyzes the worldwide markets for Neurodegenerative Drugs in US$ Million by the following disease types: Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, Amyotrophic Lateral ...
Global Neuromodulation Market 2009-2013 by
Infiniti Research Limited
Neuromodulation consist of devices, which are implantable, wireless controlled and delivers electrical current at targeted nerve fibers, to treat a patient's disabling neurological condition. It ...
World Neurodegenerative Diseases Market 2009-2024 by
Visiongain
The ageing of the baby-boom generation, combined with new and emerging treatments for neurodegenerative disorders - including multiple sclerosis, Alzheimer's disease and Parkinson's disease - ...
See all reports like this >>
Related Markets
Parkinson's Disease Reports
- Parkinson's Disease Therapeutics - Global Drug Forecasts and Treatment Analysis to 2020
- Parkinson's Disease Global Clinical Trials Review, H2, 2011
- Parkinson's Disease: World Drug Market 2011-2021
- The 10th International Conference on Alzheimer's and Parkinson's Diseases: Post-Conference Review and Analysis
- Parkinson Disease Therapy Area Pipeline Report
